M-B-A Adapto-Genic Formula No. 1
Withdrawn from the US market on 3 October 2023 (according to the DSLD)
Jeunique, food supplement from the US market
Label withdrawn from the US market. M-B-A Adapto-Genic Formula No. 1 (Jeunique), a food supplement au code-barres 665971000413, is described by its US market label. If sold in France, it would be subject to 3 points of French or European regulation, detailed below. Doses of niacine are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine C: up to 375 mg a day according to the label (at most 3 servings a day), above the maximum dose of 180 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 37.5 mg a day according to the label (at most 3 servings a day), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- À vérifier
Vitamine B6: up to 37.5 mg a day according to the label, above the tolerable upper intake level from EFSAEuropean Food Safety Authority. for adults (12 mg a day). The EFSA reference covers total daily intake, from food and supplements.
Source: EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), limite supérieure de sécurité (UL).
- Conditions légales
Frangula purshiana Cooper: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes ainsi qu'une mention déconseillant l'usage prolongé.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Jeunique
- Barcode
- 665971000413
- Form
- Other (for example, tea bag)
- One serving
- 1 caplet
- Servings
- up to 3 servings per day
- Other ingredients (in English, as written)
- Stearic Acid, Silicon Dioxide, Magnesium Stearate, Hydroxy Propyl Methyl Cellulose, Propylene Glycol
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin C | Vitamin | 125 mg |
| Vitamin E | Vitamin | 50 UI |
| Niacin | Vitamin | 50 mg |
| Vitamin B6 | Vitamin | 12.5 mg |
| Calcium | Mineral | 144 mg |
| Phosphorus | Mineral | 37 mg |
| Cascara Sagrada (Frangula purshiana) | Plant | 50 mg |
| Chickweed (Stellaria media) | Plant | 50 mg |
| Apple Cider Vinegar | Plant | 50 mg |
| Gentian | Plant | 50 mg |
| Ginger | Plant | 50 mg |
| Rhubarb | Plant | 50 mg |
| Yellow Dock | Plant | 25 mg |
| Kelp | Other | 10 mg |
| Lecithin | Fat | 10 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: M-B-A Adapto-Genic Formula No. 2
Entered into DSLD on 23 December 2011. Withdrawn from the US market on 3 October 2023 (according to the DSLD).- Active ingredient added : Acacia Gum (130 mg)
- Active ingredient added : Alfalfa (50 mg)
- Active ingredient added : Bromelain (50 mg)
- Active ingredient added : Capsicum (40 mg)
- Active ingredient added : Citrimax (250 mg)
- Active ingredient added : Dandelion (50 mg)
- Active ingredient added : Fennel (25 mg)
- Active ingredient added : Fo-Ti (80 mg)
- Active ingredient added : Ginkgo biloba (80 mg)
- Active ingredient added : Ginseng (80 mg)
- Active ingredient added : Gotu-Kola (80 mg)
- Active ingredient added : Guarana (80 mg)
- Active ingredient added : Hawthorn (45 mg)
- Active ingredient added : Hops (25 mg)
- Active ingredient added : Irish Moss (45 mg)
- Active ingredient added : Juniper (50 mg)
- Active ingredient added : Licorice (50 mg)
- Active ingredient added : Nettle (25 mg)
- Active ingredient added : Papain (50 mg)
- Active ingredient added : Parsley (25 mg)
- Active ingredient added : Saw Palmetto (50 mg)
- Active ingredient added : Senna (50 mg)
- Active ingredient added : Suma (50 mg)
- Active ingredient added : Uva Ursi (50 mg)
- Active ingredient added : Valerian (25 mg)
- Active ingredient added : Watercress (50 mg)
- Active ingredient added : White Willow (50 mg)
- Active ingredient added : Yerba Mate (45 mg)
- Active ingredient removed : Apple Cider Vinegar (50 mg)
- Active ingredient removed : Calcium (144 mg)
- Active ingredient removed : Cascara Sagrada (50 mg)
- Active ingredient removed : Chickweed (50 mg)
- Active ingredient removed : Gentian (50 mg)
- Active ingredient removed : Ginger (50 mg)
- Active ingredient removed : Kelp (10 mg)
- Active ingredient removed : Lecithin (10 mg)
- Active ingredient removed : Niacin (50 mg)
- Active ingredient removed : Phosphorus (37 mg)
- Active ingredient removed : Rhubarb (50 mg)
- Active ingredient removed : Vitamin B6 (12.5 mg)
- Active ingredient removed : Vitamin C (125 mg)
- Active ingredient removed : Vitamin E (50 IU)
- Active ingredient removed : Yellow Dock (25 mg)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Cascara Sagrada
Read the warning, when it applies and the studies cited
CASCARA SAGRADA - FRANGULA PURSHIANA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2020; Brinker 2010; WHO 2002).
Sources cited by Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2020; Brinker 2010; WHO 2002; Blumenthal et al. 2000).
Sources cited by Health Canada (5)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Contraindications
Do not use if you are pregnant or breastfeeding (EMA 2020; Brinker 2010; Blumenthal et al. 2000).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2020; Brinker 2010; WHO 2002).
Sources cited by Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Known adverse reactions
Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2020; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Jeunique
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “M-B-A Adapto-Genic Formula No. 1 : étiquette retirée du marché américain (Jeunique): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/665971000413-m-b-a-adapto-genic-formula-no-1-jeunique, updated 3 October 2023.